Skip to main content
. 2017 Jan 24;16(6):499–507. doi: 10.1080/15384101.2017.1282586

Figure 5.

Figure 5.

FASN expression is not upregulated along c-Met/β-catenin driven hepatocarcinogenesis. (A) Study design: activated forms of c-Met and β-catenin were hydrodynamically injected together with Cre into FASNfl/fl mice (c-Met/β-catenin/Cre, n = 4). This method allows the deletion of FASN while simultaneously expressing c-Met and β-catenin in the same FASNfl/fl hepatocytes. As a control, c-Met and β-catenin were injected in the same mice together with the empty vector (c-Met/β-catenin/pT3, n = 4). (B) Survival curve of c-Met/β-catenin/Cre mice (n = 4) and c-Met/β-catenin/pT3 injected FASNfl/fl mice (n = 4), P = 0.16. (C) Histologically, well to moderately differentiated HCC were found in both cohorts of mice and immunostaining demonstrated the low protein expression of FASN in c-Met/β-catenin/Cre HCC cells. Scale bar: 200µm for H&E and FASN, 100µm for Ki-67. Abbreviations: FASN, fatty acid synthase; HE, hematoxylin and eosin staining.